EU finalises talks with Valneva to secure a new vaccine

Valneva

Today, the European Commission concluded talks with Valneva to secure a new potential vaccine against COVID-19

The potential contract with pharmaceutical company Valneva would allow all EU Member States to purchase 30 million doses of its vaccine.

President of the European Commission, Ursula von der Leyen, said: “The continuing COVID-19 pandemic in Europe and around the globe makes it more important than ever that all Member States have access to the broadest possible portfolio of vaccines to help protect people in Europe and beyond.

“Today’s step toward reaching an agreement with Valneva further complements the EU’s vaccines portfolio and demonstrates the Commission’s commitment to find a lasting solution to the pandemic.”

Access to vaccinations for all

Stella Kyriakides, Commissioner for Health and Food Safety, said: “With this eighth vaccine, we are adding to our already broad and diversified range of vaccines in our portfolio. By doing this, we can maximise our chances of making sure that all citizens can have access to safe and effective of vaccinations by the end of 2021.

“All Member States have now started their vaccination campaigns and will start receiving an increasing number of doses in order to cover all their needs during this year.”

Valneva is a European biotechnology company developing an inactivated virus vaccine, the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

LEAVE A REPLY

Please enter your comment!
Please enter your name here